Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct 24;4(10):e881.
doi: 10.1038/cddis.2013.417.

APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase

X Peng  1 , M-Q-Z Zhang, F Conserva, G Hosny, G Selivanova, V J N Bykov, E S J Arnér, K G Wiman
Affiliations

APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase

X Peng et al. Cell Death Dis. .

Erratum in

Abstract

The low-molecular-weight compound APR-246 (PRIMA-1(MET)) restores wild-type conformation and function to mutant p53, and triggers apoptosis in tumor cells. We show here that APR-246 also targets the selenoprotein thioredoxin reductase 1 (TrxR1), a key regulator of cellular redox balance. APR-246 inhibited both recombinant TrxR1 in vitro and TrxR1 in cells. A Sec-to-Cys mutant of TrxR1 was not inhibited by APR-246, suggesting targeting of the selenocysteine residue in wild-type TrxR1. Preheated APR-246 and its conversion product methylene quinuclidinone (MQ) were much more efficient TrxR1 inhibitors than APR-246 itself, indicating that MQ is the active compound responsible for TrxR1 enzyme inhibition. TrxR1 inhibited by MQ was still functional as a pro-oxidant NADPH oxidase. Knockdown of TrxR1 caused a partial and reproducible attenuation of APR-246-induced tumor cell death independently of p53 status. Cellular TrxR1 activity was also inhibited by APR-246 irrespective of p53 status. We show that APR-246 can directly affect cellular redox status via targeting of TrxR1. Our findings provide an explanation for the previously observed effects of APR-246 on tumor cells lacking mutant p53.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Inhibition of TrxR1 in vitro by APR-246. (a) Preheated APR-246 and MQ efficiently inhibited TrxR1 according to the DNTB (Ellman) assay. (b) Kinetics of TrxR1 inhibition by indicated concentrations of APR-246, preheated APR-246 and MQ. (c) NADPH oxidase activity for TrxR1 treated with APR-246, preheated APR-246 and MQ as assessed by the juglone assay. (d) Sec-to-Cys variants of TrxR1 are resistant to inhibition by APR-246, preheated APR-246 or MQ. Results are means±S.E., n=3–6
Figure 2
Figure 2
Inhibition of TrxR1 activity in living cells. (a) APR-246 inhibited activity of TrxR1 in H1299, H1299-His175, Saos-2, Saos-2-His273 and BL41tsp53 cells. Results are means±S.E., n=4. (b) Treatment with APR-246 reduced the expression of TrxR1 in H1299-His175 cells according to the western blot analysis
Figure 3
Figure 3
siRNA knockdown of TrxR1 inhibits APR-246-induced cell death. (a) Two different siRNAs against TrxR1 (TrxR1-siRNA-1 and TrxR1-siRNA-2) inhibited TrxR1 expression in H1299 and H1299-His175 cells for at least 72 h. (b) H1299-His175 cells treated either with scrambled siRNA or a combination of scrambled siRNA and APR-246, or with TrxR1-siRNA-2 and APR-246. DNA content was assessed by flow cytometry. (c) Quantification of the sub-G1 cell population. Data are means±S.E., n=4
Figure 4
Figure 4
siRNA knockdown of TrxR1 inhibits generation of ROS induced by treatment with APR-246. (a) H1299-His175 cells treated either with scrambled siRNA or with a combination of scrambled siRNA and 50 μM of APR-246 or with TrxR1-siRNA-2 and 50 μM of APR-246. ROS production was estimated by DCF staining and assessed by flow cytometry. (b) Quantification of ROS levels in H1299 and H1299-His175 cells. Data are means±S.E., n=4. MFI, mean fluorescence intensity
See this image and copyright information in PMC

References

    1. Hussain SP, Harris CC. P53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer. Mutat Res. 1999;428:23–32. - PubMed
    1. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mut. 2007;28:622–629. - PubMed
    1. Soussi T, Wiman KG. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell. 2007;12:303–312. - PubMed
    1. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007;26:2157–2165. - PubMed
    1. Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene. 1999;18:477–485. - PubMed

Publication types